Literature DB >> 14768753

Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target.

A J Chalmers1.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme that binds rapidly to single and double-strand breaks in DNA and consequently modifies a range of nuclear proteins involved in the cellular response to ionising radiation. PARP-1 knockout mice are highly sensitive to ionising radiation, and inhibition or depletion of PARP-1 brings about modest sensitisation of cells in culture to radiation doses of 2 Gy and above. In certain cell lines, chemical inhibition of PARP activity is also associated with marked sensitisation to very low doses of radiation (<0.5 Gy). The mechanisms underlying these effects are discussed, and possible therapeutic applications of PARP-1 manipulation in combination with ionising radiation are considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14768753     DOI: 10.1016/s0936-6555(03)00223-1

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  11 in total

1.  Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.

Authors:  Chetan P Hans; Yumei Feng; Amarjit S Naura; Dana Troxclair; Mourad Zerfaoui; Danish Siddiqui; Ju Jihang; Hogyoung Kim; Alan D Kaye; Khalid Matrougui; Eric Lazartigues; A Hamid Boulares
Journal:  Cardiovasc Pathol       Date:  2010-05-07       Impact factor: 2.185

2.  A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Authors:  Kim A Reiss; Joseph M Herman; Deborah Armstrong; Marianna Zahurak; Anthony Fyles; Anthony Brade; Michael Milosevic; Laura A Dawson; Angela Scardina; Patricia Fischer; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lee-Anne Stayner; Lillian L Siu; Nilofer S Azad
Journal:  Gynecol Oncol       Date:  2017-01-18       Impact factor: 5.482

Review 3.  DNA repair deficiency in neurodegeneration.

Authors:  Dennis Kjølhede Jeppesen; Vilhelm A Bohr; Tinna Stevnsner
Journal:  Prog Neurobiol       Date:  2011-04-30       Impact factor: 11.685

4.  A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.

Authors:  Charles Kunos; Wei Deng; Dawn Dawson; Jayanthi S Lea; Kristine M Zanotti; Heidi J Gray; David P Bender; Perry P Guaglianone; Jori S Carter; Kathleen N Moore
Journal:  Int J Gynecol Cancer       Date:  2015-03       Impact factor: 3.437

5.  A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.

Authors:  Kim A Reiss; Joseph M Herman; Marianna Zahurak; Anthony Brade; Laura A Dawson; Angela Scardina; Caitlin Joffe; Emily Petito; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lillian L Siu; Nilofer S Azad
Journal:  Clin Cancer Res       Date:  2014-10-29       Impact factor: 12.531

Review 6.  Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.

Authors:  Stergios Boussios; Peeter Karihtala; Michele Moschetta; Charlotte Abson; Afroditi Karathanasi; Nikolaos Zakynthinakis-Kyriakou; Jake Edward Ryan; Matin Sheriff; Elie Rassy; Nicholas Pavlidis
Journal:  Invest New Drugs       Date:  2019-10-24       Impact factor: 3.850

Review 7.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

8.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.

Authors:  Lauren Shunkwiler; Gina Ferris; Charles Kunos
Journal:  Int J Mol Sci       Date:  2013-02-08       Impact factor: 5.923

9.  Induction of apoptosis by the inhibitors of poly(ADP-ribose)polymerase in HeLa cells.

Authors:  Utpal Ghosh; Nitai P Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2008-08-10       Impact factor: 3.842

10.  Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.

Authors:  Mathias Tesson; Colin Rae; Colin Nixon; John W Babich; Robert J Mairs
Journal:  J Pharm Pharmacol       Date:  2016-05-03       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.